All Updates

All Updates

icon
Filter
Partnerships
PlaqueTec collaborates with Babraham Institute to evaluate druggability of pro-inflammatory protein
Precision Medicine
May 14, 2024
Last week:
Partnerships
Geographic expansion
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Industry news
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 14, 2024

PlaqueTec collaborates with Babraham Institute to evaluate druggability of pro-inflammatory protein

Partnerships

  • PlaqueTec has collaborated with the Babraham Institute's Welch lab in evaluating the drugability of pro-inflammatory protein under BIOPATTERN trial focused on endotyping coronary artery disease (CAD). The parties have previously asserted the potential of pro-inflammatory protein to be targeted by small-molecule drugs in a human cell-culture model.

  • Based in the UK, PlaqueTec is focused on the development and application of endotype-specific biomarkers to develop novel treatments for CAD. PlaqueTec employs its proprietary Liquid Biopsy System to capture biomarkers directly from coronary arteries to provide a deeper understanding of the disease's nature and develop precise treatments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.